Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | FOXM1 | Q08050 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15388091 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2 | |
| SCHEMBL12466130 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6122857 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28735985 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28735986 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL15395672 | 0.84 | ALDH1A1 (0.42) | SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2 | |
| SCHEMBL14934953 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2 | |
| SCHEMBL19105491 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2 | |
| SCHEMBL18677293 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EFOXM1ALDH1A1CYP1A2 | |
| SCHEMBL13856214 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EFOXM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| WO-2013066684-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 3630/4885KDM4E 1116/4885FOXM1 1309/4885 |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | SMN1; SMN2 3482/4885KDM4E 1150/4885FOXM1 1175/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 3482/4885KDM4E 1150/4885FOXM1 1175/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | SMN1; SMN2 3482/4885KDM4E 1150/4885FOXM1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.